- Home
- NTLA vs EOS Comparison
NTLA vs EOS Comparison
Compare NTLA & EOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTLA
- EOS
- Stock Information
- Founded
- NTLA 2014
- EOS 2005
- Country
- NTLA United States
- EOS United States
- Employees
- NTLA N/A
- EOS N/A
- Industry
- NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- EOS Trusts Except Educational Religious and Charitable
- Sector
- NTLA Health Care
- EOS Finance
- Exchange
- NTLA Nasdaq
- EOS Nasdaq
- Market Cap
- NTLA 710.1M
- EOS N/A
- IPO Year
- NTLA 2016
- EOS N/A
- Fundamental
- Price
- NTLA $8.28
- EOS $22.01
- Analyst Decision
- NTLA Buy
- EOS
- Analyst Count
- NTLA 19
- EOS 0
- Target Price
- NTLA $38.47
- EOS N/A
- AVG Volume (30 Days)
- NTLA 3.1M
- EOS 84.1K
- Earning Date
- NTLA 05-08-2025
- EOS 01-01-0001
- Dividend Yield
- NTLA N/A
- EOS 6.80%
- EPS Growth
- NTLA N/A
- EOS N/A
- EPS
- NTLA N/A
- EOS N/A
- Revenue
- NTLA $45,569,000.00
- EOS N/A
- Revenue This Year
- NTLA N/A
- EOS N/A
- Revenue Next Year
- NTLA N/A
- EOS N/A
- P/E Ratio
- NTLA N/A
- EOS N/A
- Revenue Growth
- NTLA N/A
- EOS N/A
- 52 Week Low
- NTLA $5.90
- EOS $15.62
- 52 Week High
- NTLA $28.18
- EOS $20.63
- Technical
- Relative Strength Index (RSI)
- NTLA 51.86
- EOS 60.93
- Support Level
- NTLA $7.21
- EOS $21.52
- Resistance Level
- NTLA $9.27
- EOS $21.96
- Average True Range (ATR)
- NTLA 0.65
- EOS 0.43
- MACD
- NTLA 0.02
- EOS 0.22
- Stochastic Oscillator
- NTLA 53.33
- EOS 95.56
About NTLA Intellia Therapeutics Inc.
Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.